Logo image of SWTX

SPRINGWORKS THERAPEUTICS INC (SWTX) Stock Fundamental Analysis

NASDAQ:SWTX - Nasdaq - US85205L1070 - Common Stock - Currency: USD

46.8  0 (0%)

After market: 46.8 0 (0%)

Fundamental Rating

4

SWTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SWTX as it has an excellent financial health rating, but there are worries on the profitability. SWTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SWTX has reported negative net income.
SWTX had a negative operating cash flow in the past year.
SWTX had negative earnings in each of the past 5 years.
In the past 5 years SWTX always reported negative operating cash flow.
SWTX Yearly Net Income VS EBIT VS OCF VS FCFSWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

The Return On Assets of SWTX (-50.25%) is comparable to the rest of the industry.
The Return On Equity of SWTX (-60.84%) is better than 60.04% of its industry peers.
Industry RankSector Rank
ROA -50.25%
ROE -60.84%
ROIC N/A
ROA(3y)-44.26%
ROA(5y)-35.82%
ROE(3y)-51.76%
ROE(5y)-40.92%
ROIC(3y)N/A
ROIC(5y)N/A
SWTX Yearly ROA, ROE, ROICSWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

SWTX has a Gross Margin of 93.23%. This is amongst the best in the industry. SWTX outperforms 94.44% of its industry peers.
SWTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SWTX Yearly Profit, Operating, Gross MarginsSWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

SWTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SWTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SWTX has more shares outstanding
SWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SWTX Yearly Shares OutstandingSWTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SWTX Yearly Total Debt VS Total AssetsSWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 19.98 indicates that SWTX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.98, SWTX belongs to the top of the industry, outperforming 93.55% of the companies in the same industry.
SWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.98
ROIC/WACCN/A
WACC9.85%
SWTX Yearly LT Debt VS Equity VS FCFSWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 4.33 indicates that SWTX has no problem at all paying its short term obligations.
SWTX has a Current ratio (4.33) which is in line with its industry peers.
SWTX has a Quick Ratio of 4.18. This indicates that SWTX is financially healthy and has no problem in meeting its short term obligations.
SWTX has a Quick ratio (4.18) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.33
Quick Ratio 4.18
SWTX Yearly Current Assets VS Current LiabilitesSWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.79% over the past year.
Looking at the last year, SWTX shows a very strong growth in Revenue. The Revenue has grown by 730.42%.
EPS 1Y (TTM)33.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.93%
Revenue 1Y (TTM)730.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%133.68%

3.2 Future

Based on estimates for the next years, SWTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.73% on average per year.
The Revenue is expected to grow by 40.44% on average over the next years. This is a very strong growth
EPS Next Y24.82%
EPS Next 2Y26.17%
EPS Next 3Y33.59%
EPS Next 5Y19.73%
Revenue Next Year76.39%
Revenue Next 2Y73.57%
Revenue Next 3Y60.55%
Revenue Next 5Y40.44%

3.3 Evolution

SWTX Yearly Revenue VS EstimatesSWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
SWTX Yearly EPS VS EstimatesSWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SWTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SWTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SWTX Price Earnings VS Forward Price EarningsSWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SWTX Per share dataSWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as SWTX's earnings are expected to grow with 33.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.17%
EPS Next 3Y33.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SWTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRINGWORKS THERAPEUTICS INC

NASDAQ:SWTX (6/6/2025, 8:00:01 PM)

After market: 46.8 0 (0%)

46.8

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/amc
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners114.22%
Inst Owner Change-10.74%
Ins Owners1.89%
Ins Owner Change-4.18%
Market Cap3.52B
Analysts73.33
Price Target55.95 (19.55%)
Short Float %8.14%
Short Ratio1.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.05%
Min EPS beat(2)-44.63%
Max EPS beat(2)-35.47%
EPS beat(4)2
Avg EPS beat(4)-5.34%
Min EPS beat(4)-44.63%
Max EPS beat(4)52.52%
EPS beat(8)5
Avg EPS beat(8)-3.18%
EPS beat(12)7
Avg EPS beat(12)-2.43%
EPS beat(16)7
Avg EPS beat(16)-7.99%
Revenue beat(2)1
Avg Revenue beat(2)-12.64%
Min Revenue beat(2)-27.36%
Max Revenue beat(2)2.07%
Revenue beat(4)2
Avg Revenue beat(4)9.03%
Min Revenue beat(4)-27.36%
Max Revenue beat(4)70.52%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-24.33%
PT rev (3m)-23.72%
EPS NQ rev (1m)-4.83%
EPS NQ rev (3m)-21.68%
EPS NY rev (1m)-8.16%
EPS NY rev (3m)-26.2%
Revenue NQ rev (1m)-1.27%
Revenue NQ rev (3m)-4.21%
Revenue NY rev (1m)-3.79%
Revenue NY rev (3m)-2.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.05
P/FCF N/A
P/OCF N/A
P/B 8.45
P/tB 8.45
EV/EBITDA N/A
EPS(TTM)-3.41
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS2.92
BVpS5.54
TBVpS5.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.25%
ROE -60.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.23%
FCFM N/A
ROA(3y)-44.26%
ROA(5y)-35.82%
ROE(3y)-51.76%
ROE(5y)-40.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 524.84%
Cap/Sales 9.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.33
Quick Ratio 4.18
Altman-Z 19.98
F-Score6
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)788.2%
Cap/Depr(5y)591.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.93%
EPS Next Y24.82%
EPS Next 2Y26.17%
EPS Next 3Y33.59%
EPS Next 5Y19.73%
Revenue 1Y (TTM)730.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%133.68%
Revenue Next Year76.39%
Revenue Next 2Y73.57%
Revenue Next 3Y60.55%
Revenue Next 5Y40.44%
EBIT growth 1Y26.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.3%
OCF growth 3YN/A
OCF growth 5YN/A